Financial Data and Key Metrics Changes - The company reported Q4 revenue of $138 million, which is 4% above the high end of guidance and represents a 17% year-over-year increase [5][15] - For the full fiscal year, revenue reached $570 million, growing 20% year-over-year [6][15] - Adjusted EBITDA for Q4 was $70 million, with a margin of 50%, exceeding guidance by 10% [6][17] - Free cash flow for Q4 was $97 million, up 56% year-over-year, and for the full year, it was $267 million, an increase of 50% [6][18] - The adjusted EBITDA margin for the full fiscal year was 55%, up from 48% the previous year [6][18] Business Line Data and Key Metrics Changes - The top 20 clients grew revenue by 23% in fiscal 2025, indicating strong performance among the largest customers [6][16] - The company ended the quarter with 116 customers contributing at least $500,000 each in subscription-based revenue, a 17% increase from the previous year [16] - Unique active users across various engagement metrics reached record highs, particularly driven by the newsfeed product [7] Market Data and Key Metrics Changes - The company expects the Pharma HCP digital market to grow at approximately 5% to 7% in the upcoming year, with the company anticipating to grow at roughly twice the market rate [22] - The net revenue retention rate was 119% on a trailing twelve-month basis, with the top 20 customers at 123% [16] Company Strategy and Development Direction - The company is focusing on multi-module integrated offerings, which have led to larger deal sizes and more efficient launch timelines [15][21] - There is a strong emphasis on AI investments to enhance tools for members and clients, with expectations of significant long-term benefits [23] - The company aims to maintain a competitive position in the Pharma sector, which is projected to be the fastest-growing business segment [22] Management's Comments on Operating Environment and Future Outlook - Management has not observed any signs of market slowdown but is cautious due to macroeconomic uncertainties [25][30] - The mood among pharma clients is described as cautiously optimistic, with excitement around AI tools [30] - The company is preparing for potential impacts from policy uncertainties while maintaining a positive outlook on growth [40][41] Other Important Information - The company repurchased $26.8 million worth of shares in Q4 and $116.2 million for the full fiscal year [18] - The company ended the year with $916 million in cash, cash equivalents, and marketable securities [18] Q&A Session Summary Question: How are customer conversations regarding spending in the current macro environment? - Management noted that there have been no signs of a market slowdown yet, but they are assuming some material policy uncertainty [25][30] Question: What is the expected payback period for AI investments? - Management indicated that it is still early to determine the exact impact of AI on long-term margins, but they are already seeing benefits from AI investments [31][33] Question: How does the company view the impact of potential drug pricing constraints? - Management acknowledged discussions around drug pricing but noted that clients typically have separate teams for direct-to-consumer marketing, making immediate impacts less likely [52][54] Question: What is the outlook for revenue growth and seasonality? - Management expects a more predictable revenue curve due to integrated programs and anticipates Q3 to be the highest quarter due to upselling [97][98] Question: How is the company addressing the allocation of budgets across digital channels? - Management reported that clients are leaning more into endemic channels, with no signs of slowing growth for their offerings [62][63]

Exhibit 99.1 Doximity Announces Fourth Quarter and Fiscal Year 2025 Financial Results Q4 total revenues of $138.3 million, up 17% year-over-year Q4 operating cash flow of $98.5 million, up 54% year-over-year Q4 free cash flow of $97.0 million, up 56% year-over-year Fiscal year 2025 total revenues of $570.4 million, up 20% year-over-year Fiscal year 2025 operating cash flow of $273.3 million, up 48% year-over-year Fiscal year 2025 free cash flow of $266.7 million, up 50% year-over-year SAN FRANCISCO, Calif., ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company’s business and operations. Specifically, the Complaint alleges Defendants repeatedly touted the Company’s business pro ...

Doximity (DOCS) is scheduled to release fourth-quarter fiscal 2025 results on May 15, after market close. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 36.36%. DOCS delivered a trailing four-quarter average earnings surprise of 26.00%.DOCS Q4 EstimatesCurrently, the consensus estimate for revenues is pegged at $133.8 million. The consensus mark for earnings is pinned at 27 cents per share.Factors to NoteDoximity’s fourth-quarter fiscal 2025 performance is expected ...

Doximity, Inc. (NYSE: DOCS ) operates an online platform service which saw huge growth in user engagement, especially among medical prescribers. Such a growth momentum is expected to persist, fuelled by the pharmaceutical marketing segment, which was identified as the segmentAs a self-taught retail investor, I’m interested to share insights through thoughtful, research-driven articles. I’m glad you’ve taken the time to visit my profile, and I hope my content provides value and sparks new ideas for your inve ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech-driven innovators. Tempus AI (TEM) and Doximity (DOCS) stand out as emerging players in the AI health tech space. These two offer distinct approaches to innovation and market disruption.Tempus AI is focused on leveraging AI-driven precision medicine, particularly in oncology and chronic disease management, while Doximity operates as a digital platform connecting medical professionals ...

In the latest trading session, Doximity (DOCS) closed at $60.55, marking a -1.51% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.33%. On the other hand, the Dow registered a loss of 0.37%, and the technology-centric Nasdaq decreased by 0.53%.The medical social networking site's stock has dropped by 15.67% in the past month, falling short of the Medical sector's loss of 3.24% and the S&P 500's loss of 4.03%.Investors will be eagerly watching for the performance of ...

Company Performance - Doximity (DOCS) closed at $62.99, with a +0.35% change from the previous day's closing price, outperforming the S&P 500 which gained 0.08% [1] - Over the past month, Doximity's shares have decreased by 16.31%, while the Medical sector and S&P 500 have lost 1.03% and 7.33% respectively [1] Upcoming Earnings - Analysts expect Doximity to report an EPS of $0.27, reflecting an 8% increase year-over-year, with projected revenue of $133.76 million, up 13.3% from the same quarter last year [2] - For the annual period, earnings are anticipated to be $1.31 per share and revenue at $562.98 million, indicating increases of +37.89% and +18.42% respectively from the previous year [3] Analyst Sentiment - Recent revisions in analyst estimates suggest optimism regarding Doximity's business and profitability, with a 1.52% increase in the Zacks Consensus EPS estimate over the last 30 days [3][5] - Doximity currently holds a Zacks Rank of 1 (Strong Buy), which has historically provided an average annual return of +25% since 1988 [5] Valuation Metrics - Doximity's Forward P/E ratio stands at 47.99, significantly higher than the industry's Forward P/E of 16.32, indicating a premium valuation [6] - The company's PEG ratio is currently 2.6, compared to the average PEG ratio of 1.43 for Medical Services stocks [6] Industry Context - The Medical Services industry, part of the broader Medical sector, holds a Zacks Industry Rank of 75, placing it in the top 30% of over 250 industries [7] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7]

Core Insights - Investors seek stocks that can outperform market expectations ahead of earnings season, focusing on high-quality stocks [1] - Positive earnings surprises are crucial as stocks often decline if they miss or merely meet expectations, regardless of nominal earnings growth [2][3] - A significant earnings surprise can lead to a substantial increase in stock price immediately after the earnings release [4] Stock Selection Criteria - Stocks with a last EPS surprise of at least 10% are more likely to surprise again [7] - An average EPS surprise of over 20% in the last four quarters indicates strong potential for future earnings beats [8] - A Zacks Rank of 1 (Strong Buy) or 2 (Buy) is required for stocks to be considered [8][9] - Positive Earnings ESP is necessary for a stock to achieve an earnings beat [9] - Long-term growth potential is assessed through estimated EPS growth of over 10% per year and an average trading volume exceeding 100,000 [10] Highlighted Stocks - **Doximity (DOCS)**: Zacks Rank 1, average earnings surprise of 26.00% over the past four quarters [11] - **Life Time Group Holdings (LTH)**: Zacks Rank 1, average earnings surprise of 21.58% [12] - **Adtalem Global Education (ATGE)**: Zacks Rank 1, average earnings surprise of 21.58% [13] - **BioMarin Pharmaceutical (BMRN)**: Zacks Rank 2, average earnings surprise of 32.36% [14] - **Iridium Communications (IRDM)**: Zacks Rank 2, average earnings surprise of 35.22% [14]

Core Viewpoint - U.S. stock markets are experiencing significant volatility, primarily due to tariff and trade policies from the Trump administration, alongside signs of a softening economy [1][2] Industry Overview - The health and fitness industry is witnessing growing demand driven by increased global awareness of health issues and the importance of physical fitness, supported by rising lifestyle-related diseases and a focus on preventive healthcare [4] - The industry's growth is bolstered by diverse revenue streams, including subscriptions, product sales, and services, making it attractive for long-term investment [5] - Technological advancements, such as fitness trackers and wearable devices, are creating new growth opportunities and enhancing consumer engagement [5] Company Highlights - **Garmin Ltd. (GRMN)**: - Zacks Rank 1, benefiting from strong momentum in Fitness and Auto OEM segments, with a projected revenue CAGR of 9.3% from fiscal 2025-2027 [11][12] - Expected revenue and earnings growth rates of 9.7% and 8% for the current year, respectively [12] - **Sprouts Farmers Market Inc. (SFM)**: - Zacks Rank 1, focusing on product innovation and e-commerce, with net sales expected to rise between 10.5% and 12.5% in 2025 [13][14] - Expected revenue and earnings growth rates of 12.1% and 21.6% for the current year, respectively [15] - **Doximity Inc. (DOCS)**: - Zacks Rank 1, providing a digital platform for medical professionals, with expected revenue and earnings growth rates of 11.5% and 8.1% for the next year [16][17] - **Life Time Group Holdings Inc. (LTH)**: - Zacks Rank 1, offering a range of health and wellness experiences, with expected revenue and earnings growth rates of 12.9% and 36.8% for the current year [18][20] - **V.F. Corp. (VFC)**: - Zacks Rank 2, showing strong performance in revenues and earnings, with expected growth rates of 2.3% and 46.2% for the next year [21][23]